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Summary Regional chemotherapy for colorectal liver metastases has not demonstrated a convincing survival
benefit over systemic chemotherapy. This may be due to poor delivery of chemotherapeutic drugs to
hypovascular liver tumour. Since vasoactive agents may influence hepatic blood flow this study investigated
the effects of systemic and regional vasoconstrictors on the delivery of a regionally delivered marker in an
experimental model of liver tumour.
Systemic administration of angiotensin II caused a significant retention ofmarker in normal liver, but not in
tumour compared to controls.
Regional delivery of angiotensin II and phenylephrine caused significantly greater retention of marker in
tumour than liver with an overall 4-fold increased retention of marker one minute after its injection. Ninety
minutes after injection there was still significant retention of marker compared to control animals. Regional
delivery of hepatic artery vasoconstrictors increase delivery of marker and may increase delivery of
chemotherapeutic drug to liver tumour.
A substantial proportion of patients with colorectal cancer
develop hepatic metastases and, in the majority, the liver is
the only site of recurrence (Rapoport & Burleson, 1970;
Russell et al., 1984; Finlay & McArdle, 1983). Systemic
chemotherapy does not improve survival and is associated
with significant undesirable, unpleasant and sometimes fatal
side-effects (Kemeny et al., 1980). In recent years interest has
been accumulating in regional chemotherapy for the treat-
ment of hepatic metastases derived from colorectal primaries.
The rationale of the treatment is that higher concentration of
cytotoxic drugs metabolised by the liver can be infused via
the hepatic artery and are retained within the organ minimis-
ing the systemic side-effects (Ensminger et al., 1978; Sigurd-
son et al., 1986). Furthermore, because the blood supply of
overt hepatic metastases is derived principally from the
hepatic artery (Ackerman et al., 1969; Taylor et al., 1979) it
was postulated that the tumour should retain more of the
cytotoxic drug than normal liver cells.
Although regional hepatic artery chemotherapy improves
the tumour response rates compared to systemic chemo-
therapy (Kemeny et al., 1987), survival is not affected. The
disappointing results of regional chemotherapy may be re-
lated to the relatively hypovascular nature of the majority of
liver metastases (Taylor et al., 1979) which limits presenta-
tion of the drug to the tumour. Numerous vasoactive drugs
have been used to manipulate hepatic blood flow in tumour
bearing patients and animals (Sasaki et al., 1985; Burton &
Gray, 1987). Histological studies have shown that the blood
vessels of tumour are undifferentiated, composed only of
endothelium, lack muscular or venous elements, and thus
would have no adrenergic innvervation (Mattson et al.,
1977). These observations suggest that vasoactive drugs
would have a maximal effect on the normal liver vasculature,
with little or no effect on the tumour vessels (Mattson et al.,
1978). This hypothesis was supported by observations which
demonstrated that angiotensin II, an hepatic arterial vaso-
constrictor, increased the tumour:normal tissue blood flow
ratio when infused into the hepatic artery (Sasaki et al.,
1985). However, these studies did not demonstrate whether
the intrahepatic blood flow changes induced by angiotensin
II result in an increased delivery of chemotherapeutic drug to
liver tumour. Other vasoconstrictor agents have been used to
manipulate blood flow to subcutaneous tumours. For exam-
ple, phenylephrine has been shown to increase the relative
blood flow to subcutaneous tumours compared to surround-
ing tissue and does not have the disadvantage of the rebound
hypotension observed with angiotensin II and some other
vasoconstricting agents (Chan et al., 1984).
We have developed a model of hypovascular liver tumour
in the rat, and a technique using a radiolabelled marker of
similar molecular size to cytotoxic drug to determine whether
manipulation of intrahepatic blood flow by vasoactive agent
increases its delivery and retention by liver tumour relative to
normal liver tissue (Cooke & Chang, 1990; Hemingway et al.,
1989a). The marker, 9'Tc Methylene Diphosphonate (MDP)
is non-ionic, diffusable and is not actively taken up by
hepatocytes. Therefore, any change in the relative retentions
of MDP by normal tissue must be due to a redistribution
secondary to alterations in hepatic haemodynamics.
The aim of this study was to investigate the effects of
regional and systemic administration of angiotensin II and
phenylephrine on the distribution of regionally delivered
marker to normal liver tissue and tumour in rats.
Methods
Induction of tumour
Metastases were induced in male hooded Lister rats,
(200-250g body weight), by intraportal inoculation of 106
HSN sarcoma cells. In this experimental model overt liver
tumour is apparent approximately three weeks after inocula-
tion of the sarcoma cells.
We have previously characterised the haemodynamic chan-
ges associated with the growth and development of this
tumour (Cooke & Chang, 1990; Hemingway et al., 1989b,).
Briefly, overt tumour derives its blood supply almost entirely
from the hepatic artery, with a minimal contribution by the
portal vein, is relatively hypovascular compared to the sur-
rounding normal liver (tumour:liver blood flow ratio 0.6:1)
and exhibits no arteriosystemic shunting. This hepatic tu-
mour therefore displays many of the haemodynamic charac-
teristics of hepatic metastases derived from colorectal pri-
mary tumours in man.
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Marker distribution
Tumour bearing rats were anaesthetised with sodium pen-
tobarbitone (Sagatal, 30 mg kg-'), and a silastic catheter
(Portex, Hythe, UK, outside diameter 0.61 mm) introduced
into the gastroduodenal artery. The cannula was positioned
so that its tip lay at the junction of the coeliac and hepatic
arteries. Under direct vision, using an operating microscope,
an injection of normal saline was administered via the can-
nula to ensure the injectate passed into the hepatic artery and
not down the coeliac artery.
A second cannula was introduced into the right femoral
artery for continuous measurement ofthe arterial blood pres-
sure using a strain gauge transduce attached to a Gould pen
recorder (Gould Medical Ltd., Lutterworth, UK). The left
femoral vein was cannulated for systemic infusion of angio-
tensin II where necessary.
Controls
Twenty control rats received an intrahepatic arterial bolus of
saline via the cannula in the gastroduodenal artery. Thirty
seconds later 50"l of 9'9Tc MDP (100 MBqml-') was
infused via the the hepatic artery under direct vision over
30 s. Ten animals were killed at one, and 10 animals at
90 min after the injection. The tumour was dissected from
normal liver tissue, weighed and placed in vials for counting
on a well gamma counter (Packard, UK).
Systemic Angiotensin II
Angiotensin II (Ciba-Geigy) diluted in normal saline to a
concentration of 0.83 ggml-', was infused through the
venous cannula at a rate of 3.6,gmin-' g x I0-. In ten
rats, 90 s after commencing the infusion (i.e., the peak of the
blood pressure response) 50iLl of 9'Tc labelled MDP
(100 MBq m-') was injected via the hepatic arterial catheter
over 30 s. One minute later the ten animals were killed,
tumour was dissected from normal liver tissue, and gamma
counted as described above.
Intra-arterial Angiotensin
Angiotensin II (Ciba-Geigy) was diluted in normal saline to a
concentration of 5 jig ml-'. Fifty1l (0.25fig) was injected
over 30 s via the hepatic artery. Thirty seconds later 50iLl of
99mTc MDP (100 MBqml-') was infused via the hepatic
artery under direct vision. Ten animals were killed at 1 and
10 at 90 min after injection and the radioactivity in the liver
and tumour counted.
over 30 s into the hepatic artery followed 30 s later by 50y1
of MDP labelled with 9'9Tc (100 MBq per ml). Ten rats were
killed at 1 and 10 at 90 min after injection and liver and
tumour counted as before.
A reference sample of MDP was withdrawn from the stock
solution immediately after the hepatic artery injections and
counted immediately prior to the samples. The counts were
corrected for decay of 9'Tc and the results expressed as
percentage of the injected dose (% ID) per gram of tissue.
Statistical analysis of the distribution of labelled marker
between liver and tumour in control and experimental
animals was by non-parametric Mann-Whitney test.
Results
Mean hepatic replacement
The mean hepatic replacement by tumour was 27.3 ± 15.2%
(mean ± s.d.).
Angiotensin II
Intravenous infusion
Distribution of marker During systemic administration of
angiotensin II the percentage injected dose of regionally
delivered MDP per gram of liver at one minute
(16.0 ± 5.4 x 10-1 mean ± s.d.) was significantly greater
(P<0.02) than in control animals (3.55 ± .15. x 10-1).
However the percentage injected dose of MDP per gram for
tumour in angiotensin treated rats (9.6 ± 3.0 x 10-1) was
not significantly greater than that in control animals
(5.17 ± 0.55 x 10-1) (Figure 1). The tumour:liver ratio in
rats infused with angiotensin II was 0.6:1 compared to 1.5:1
in controls.
Blood pressure Arterial blood pressure rose from
117.8 ± 14.8 mmHg to 149 ± 22.4 mmHg after IV infusion of
angiotensin II. The time from the commencement of the
angiotensin II infusion to the first change in blood pressure
was 8.14 ± 7.58 s and the maximal effect was observed at
29.0 ± 19.8 s. In four of the rats, the peak blood pressure was
maintained until the animals were killed one minute after the
MDP injection.
Intra-arterial angiotensin II
Distribution ofmarker
Intra-arterial Phenylephrine
Phenylephrine solution 10 mg per ml (Boots, Ltd) was
diluted 1 in 50 with 0.9% saline. Fifty ftl (10pg) was infused
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Figure 1 The distribution of marker between liver and tumour
after systemic angiotensin II infusion.
One minute The percentage ofthe injected dose of MDP per
gram of normal liver tissue in angiotensin II treated rats
(11.1 ± 1.1 x 10-1) was significantly greater (P<0.02) than
in control animals (3.55 ± 0.15 x 10-1). Similarly the percen-
tage injected dose of marker per gram in tumour tissue
(23.1 ± 5.7 x 10-1) was significantly greater in angiotensin II
treated animals (P<0.01) than that in controls
(5.17 ± 0.55 x 10-1) (Figure 2). The tumour:liver ratio .at
one minute in angiotensin II treated rats was 2.1:1.
90 minutes Ninety minutes after the intra-arterial injection
of MDP and angiotensin II there was still significant reten-
tion (P<0.01) of MDP both in normal liver
(6.4± 1.4 x 10-1) and in tumour (3.1 ± 1.07 x 10-1) com-
pared to controls normal liver (0.79 ± 0.07 ± 10-1) and
tumour (0.61 ± 0.04 x 10-1) (Figure 3).
Arterial blood pressure Arterial blood pressure rose from
114.3 ± 14.8 mmHg (mean ± s.d.) to a maximum of
142 ± 22.4 mmHg after the intra-arterial injection of
angiotensin II. The time from injection of the IA bolus of
angiotensin II to the first change in blood pressure was
8.25 ± 1.47 s and the maximal change in time to peak occur-
red at 19.25 ± 0.61 s.VASOCONSTRICTORS AND MARKER DISTRIBUTION TO LIVER TUMOUR 497
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Figure 2 The distribution of marker between liver and tumour
after intra-arterial angiotensin injection 1 min after marker injec-
tion.
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Figure 3 The effect of intra-arterial angiotensin II on the distri-
bution of marker 90 min after marker injection.
Intra-arterialphenylephrine
Distribution ofmarker
One minute The percentage injected dose of MDP per gram
of marker retained in normal liver in phenylephrine treated
rats (9.62 ± 2.5 x 10-1) was significantly greater (P <0.02)
than in control animals (3.55 ± 01.04 x 10-1). Similarly, the
percentage injected dose per gram of marker retained in
tumour (21.7 ± 5.69 x 10-1) was significantly greater
(P <0.01) than in control animals (5.17 ± 0.55 x 10-1)
(Figure 4). The tumour:liver ratio 1 min after injection of
phenylephrine was 2.25:1 indicating relatively greater reten-
tion of the marker within tumour than liver.
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Figure 4 The distribution of marker between liver and tumour
after intra-arterial phenylephrine injection 1 min after marker
injection.
90 minutes Ninety minutes after the bolus injection of MDP
there was still significant retention of marker compared to
controls both in tumur (6.9 ± 2.6 x 10-1; controls
0.61 ± 0.04 x 10-1) and in normal liver (5.9 + 0.11; controls
0.79 ± 0.07 x 10-1; P <0.01) (Figure 5).
Arterial bloodpressure
The mean arterial blood pressure rose from 88 ± 7.4 mmHg
(mean ± s.d.) to 135 ± 8.3 mmHg after phenylephrine injec-
tion. The time to the first change in blood pressure was
7.83 ± 3.37 s (mean ± s.d.) and the time to maximal response
was 14.1±6.48s.
Discussion
The prognosis for patients with liver metastases derived from
colorectal carcinoma remains poor. Resection of the meta-
stases is rarely feasible and systemic chemotherapy does not
in general prolong survival (Hughes et al., 1986; Kemeny et
al., 1980), although recent studies of systemic 5-FU and
leucovorin have shown a minor survival benefit (Kerr, 1989).
Similarly, although regional chemotherapy has produced
objective tumour responses in up to 50% of patients it has
not be demonstrated to significantly improve survival
(Kemeny et al., 1987). A possible explanation of the failure
of regional chemotherapy to improve survival in these
patients is that there is no preferential delivery of the
cytotoxic drug to the tumour (Sigurdson, 1986) since many
are relatively hypovascular compared to the surrounding liver
parenchyma.
The study by Daly et al. which demonstrated improved
response rates to regional chemotherapy in patients with
hypervascular metastases compared to patients with hypovas-
cular metastases (Daly, 1985) and which reported improved
FUDr uptake in metastases which had a high uptake of
MAA would appear to support this hypothesis (Daly et al.,
1985).
Sasaki infused 8'm Krypton into the hepatic artery of
patients with liver tumours and estimated arterial flow to
liver and tumour from the detected radioactivity in both
tissues (Sasaki et al., 1985). They demonstrated that the ratio
of tumour to liver blood flow increased to 3.3:1 after an
intra-arterial infusion of angiotensin II. The preferential sup-
ply of blood to tumour observed in their study is similar to
the results of this study in which angiotensin II and
phenylephrine enhanced the retention of an inert marker
resembling chemotherapeutic drug by hepatic tumour. Intra-
arterial administration of angiotensin II resulted in a
significant retention of marker in both normal liver tissue
and tumour. One minute after administration the retention of
the marker was increased 4-fold within the tumour compared
to control animals. Since the retention of marker in tumour
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Figure 5 The effect of intra-arterial phenylephrine on the distri-
bution of marker 90 min after marker injection.
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was greater than that of normal liver there was also an
increase in the tumour: liver ratio to 2.1:1 in experimental
animals. Phenylephrine which is also an hepatic arterial
vasoconstrictor produced similar results to angiotensin II.
One minute after administration of the phenylephrine both
tumour and liver retention of marker were increased with a
tumour:liver ratio of 2.1: 1. The experiments with both agents
indicate that regionally delivered vasoconstrictors increase
delivery of a marker to liver tumour. The findings of this
investigation are similar to our previously reported results
with degradable starch microspheres (Cooke & Chang, 1990).
Concomitant administration of degradable starch micro-
spheres and marker produced significant retention of marker
in both liver and tumour. In this study, 1 min after admini-
stration of DSM the tumour:liver ratio was 2.3:1. Angioten-
sin II, phenylephrine and DSM would therefore appear to
effect an intrahepatic redistribution of blood, diverting blood
flow and marker towards liver tumour.
Our results are also in agreement with those of Sasaki
using intravenous infusions of angiotensin II to manipulate
tumour blood flow. Intravenous angiotensin II did not con-
sistently improve the tumour:liver blood flow ratio and was
less than 1:1 for the first 2 min of his experiments. The
findings are similar to those of this study in which the
concentration of marker was greater than in tumour after IV
angiotensin II, with a tumour:liver ratio of 0.6:1.
The effects of angiotensin II on systemic and hepatic
haemodynamics are transient and of short duration, and the
administration of this vasoactive agent is occasionally fol-
lowed by a rebound hypotension. The maximum change in
liver blood flow occurs before the maximum change in blood
pressure and the regionally delivered marker must be given
during the period when there is maximum alteration in liver
blood flow. Ninety minutes after a single IA bolus injection
of phenylephrine or angiotensin, although systemic
haemodynamics had returned to the baseline values, the
retention of marker in both liver and tumour was
significantly greater than in control animals. In the control
animals, however, the marker was rapidly washed out of
both the normal liver and tumour by the hepatic arterial and
portal venous flows resulting in minimal retention at 90 min.
This study contrasts with our previously reported findings
using DSM where almost all the marker was washed out of
the normal liver at 90 min, presumably by restoration of
portal venous flow after degradation of the microspheres. It
suggests that the effects of arterial vasoconstrictors on the
intrahepatic vasculature persist for longer periods than the
effects on systemic blood pressure which are transient and
only last for approximately 3 min after the injection. Alterna-
tively, the marker may be already outside the vascular space,
either in the interstitial tissues or within the cells which
results in a reduction of marker wash out. However, this
explanation seems unlikely since the marker is washed out of
both normal liver tissue and tumour control animals.
The results of this study suggest that hepatic arterial
vasoconstrictors can improve drug delivery to liver tumour,
especially hypovascular tumours and may improve the results
of regional chemotherapy.
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